

Carlo Casali

Dipartimento di Scienze e Biotecnologie  
Medico-Chirurgiche

Università Roma Sapienza

Polo Pontino – ICOT Latina

Con il Patrocinio di:



HEREDITARY SPASTIC PARAPLEGIA  
Taking Steps Toward a Cure

P.S.E.: DALLA GENETICA  
ALLA QUOTIDIANITA'



Con il contributo di:



Sassari, 06/10/2018

Hotel Marini  
Via Pietro Nenni, 2  
(Sala Pitagora)

Nuove metodologie di analisi  
genetica: Successi e problematiche -

2

# Pannello geni HSP – Fondazione Stella Maris – Pisa – Dott. Santorelli

Data accettazione: 19/12/2013

Data di inizio dell'esecuzione del test: 06/06/2018

Provenienza: Prof. C. Casali, Neurologia, Università Sapienza, Polo Pontino, Latina

**Indicazione clinica all'indagine:** Paraparesi spastica ereditaria

**Materiale esaminato:** DNA

**Metodica utilizzata:** Target re-sequencing con piattaforma MiSeq Illumina. Le sonde utilizzate per l'esperimento sono state disegnate secondo la tecnologia SureSelect, con ibridazione bridge PCR

Sequenziamento degli esoni codificanti dei seguenti geni: *ABCD1, ACBD5, ADAR, AFG3L2, ALDH18A1, ALS2, AMPD2, AP4B1, AP4E1, AP4M1, AP4S1, AP5Z1, ARL6IP1, ARSI, ATAD3A, ATLI, ATL3, ATP13A2, ATP2B4, B4GALNT1, BICD2, BSCL2, C12ORF65, C19ORF12, C9ORF72, CAPN1, CCT5, COASY, CPT1C, CYP27A1, CYP2U1, CYP7B1, DARS2, DDHD1, DDHD2, DSTYK, DYNC1H1, ENTPD1, EPT1, ERLIN1, ERLIN2, EXOSC3, EXOSC8, FA2H, FARS2, FBXO7, FLRT1, GAD1, GBA2, GCHI, GDAP1, GDAP2, GJA1, GJC2, GLB1, HSPD1, IBA57, IFIH1, KCNA2, KIAA0196, KIF1A, KIF1C, KIF5A, KY, L1CAM, LYST, MAG, MARS, MARS2, MFN2, MTHFR, MTPAP, NIPAI, NPC1, NT5C2, OPA1, OPA3, PANK2, PEX16, PGAP1, PLA2G6, POLR3A, RAB3GAP2, REEP1, REEP2, RNASEH2B, RTN2, SACS, SAMHD1, SERAC1, SETX, SLC16A2, SLC33A1, SOX10, SPAST, SPG11, SPG20, SPG21, SPG7, TECPR2, TFG, TRMT5, TRPV4, TTC19, TUBB4A, UBQLN2, UCHL1, USP8, VAMP1, VCP, VPS37A, VRK1, WDR48, ZFR, ZFYVE26, ZFYVE27*


**Risultati:** L'analisi eseguita ha identificato le varianti di significato patogenetico incerto riportate in tabella.

**Commenti:** I dati ottenuti vanno interpretati nel contesto del quadro clinico e nell'ambito della consulenza genetica allargata.

117 geni  
!


# Fam St- *AP5Z1*/*SPG48*

mut in *AP5Z1* : c.1312-1G>T + c.2287G>A (p.V763M)




## ▼ Inheritance

The transmission pattern of SPG48 in the family reported by Slabicki et al. (2010) was consistent with autosomal recessive inheritance. 🧠





NGS data from patient II.2




# Fam Z – *ERLIN2*/*SPG18*

mut c.502G>A (p.V168M) – *ERLIN2*



NGS data from patient II.1



A novel heterozygous variant in *ERLIN2* causes autosomal dominant pure hereditary spastic paraplegia


S. L. Rydning<sup>a,b,\*</sup>, A. Dudsek<sup>c,d,\*</sup>, F. Rimmele<sup>c,d</sup>, C. Funke<sup>e</sup>, S. Krüger<sup>e</sup>, S. Biskup<sup>e,f</sup>, M. D. Vigeland<sup>g</sup>,  
H. S. Hjorthaug<sup>g</sup>, Y. Sejersted<sup>g</sup>, C. Tallaksen<sup>a,b</sup>, K. K. Selmer<sup>a,g</sup> and C. Kamm<sup>c</sup> 

<sup>a</sup>Institute of Clinical Medicine, University of Oslo, Oslo; <sup>b</sup>Department of Neurology, Oslo University Hospital, Oslo, Norway;  
<sup>c</sup>Department of Neurology, University of Rostock, Rostock; <sup>d</sup>German Center for Neurodegenerative Diseases (DZNE), Rostock,  
Germany; <sup>e</sup>CeGaT GmbH, Center for Genomics and Transcriptomics, Tübingen; <sup>f</sup>Hertie-Institute for Clinical Brain Research and German  
Center for Neurodegenerative Diseases (DZNE), University of Tübingen, Tübingen, Germany; and <sup>g</sup>Department of Medical Genetics,  
Oslo University Hospital, Oslo, Norway



# Fam L – ADAR

mut. c.164C>T (p.P55L) – ADAR




*No relatives for segregation studies.*

# 225750

AICARDI-GOUTIERES SYNDROME 1; AGS1

*Alternative titles: symbols*

AGS  
ENCEPHALOPATHY, FAMILIAL INFANTILE, WITH INTRACRANIAL CALCIFICATION  
AND CHRONIC CEREBROSPINAL FLUID LYMPHOCYTOSIS  
CREE ENCEPHALITIS  
PSEUDOTOXOPLASMOSIS SYNDROME



NGS data

## Mutations in ADAR1, IFIH1, and RNASEH2B Presenting As Spastic Paraplegia

Yanick J. Crow<sup>1,2,3</sup> Maha S. Zaki<sup>4</sup> Mohamed S. Abdel-Hamid<sup>5</sup> Ghada Abdel-Salam<sup>4</sup>  
Odile Boespflug-Tanguy<sup>6,7</sup> Nuno J. V. Cordeiro<sup>8</sup> Joseph G. Gleeson<sup>9</sup> Nirmala Rani Gowrinathan<sup>10</sup>  
Vincent Laugel<sup>11</sup> Florence Renaldo<sup>12,13,14</sup> Diana Rodriguez<sup>15</sup> John H. Livingston<sup>16</sup> Gillian I. Rice<sup>3</sup>

# L'ansia da diagnosi

- Ansia del medico e del paziente
- Cosa fare per pazienti con e senza diagnosi:
  - Gestione clinica globale
  - Informazione e formazione
  - Riabilitazione

# Presca in carico

- Attività fondamentale
- Diagnosi clinica e genetica
- Riabilitazione come processo globale
  - Fisioterapia
  - Riabilitazioni speciali (logopedia, deglutizione, respiratoria)
  - Ortesi e ausili
  - Terapia occupazionale
  - Continuità assistenziale
  - Aspetti sociali e psicologici